0
0
Overview
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and is updated regularly as new evidence emerges.
This eighth version of the WHO living guideline now contains 14 recommendations, including three new recommendations regarding Janus kinase (JAK) inhibitors and sotrovimab. No further updates to the previous existing recommendations were made in this latest version.
The WHO Therapeutics and COVID-19: living guideline currently includes a:
-
- ** NEW ** strong recommendation for the use of baricitinib as an alternative to interleukin-6 (IL-6) receptor blockers, in combination with corticosteroids, in patients with severe or critical COVID-19 (published 14 January 2022);
- ** NEW ** conditional recommendation against the use of ruxolitinib and tofacitinib for patients with severe or critical COVID-19 (published 14 January 2022);
- ** NEW ** conditional recommendation for the use of sotrovimab in patients with non-severe COVID-19, conditional for those at highest risk of hospitalization (published 14 January 2022);
- strong recommendation against convalescent plasma in patients with non-severe COVID-19 (published 7 December 2021);
- recommendation not to use convalescent plasma in patients with severe or critical COVID-19 except in the context of a clinical trial (published 7 December 2021);
- conditional recommendation to use a combination of neutralizing monoclonal antibodies (casirivimab and imdevimab) in non-severe COVID-19 patients at the highest risk of severe disease (published 24 September 2021);
- conditional recommendation to use a combination of neutralizing monoclonal antibodies (casirivimab and imdevimab) in severe and critically ill COVID-19 patients with seronegative status (published 24 September 2021);
- strong recommendation to use IL-6 receptor blockers (tocilizumab or sarilumab) in patients with severe or critical COVID-19 (published 6 July 2021);
- recommendation not to use ivermectin in patients with COVID-19 except in the context of a clinical trial (published 31 March 2021);
- strong recommendation against hydroxychloroquine in patients with COVID-19 of any severity (published 17 December 2020);
- strong recommendation against lopinavir/ritonavir in patients with COVID-19 of any severity (published 17 December 2020);
- conditional recommendation against remdesivir in hospitalized patients with COVID-19 (published 20 November 2020);
- strong recommendation to use systemic corticosteroids in patients with severe and critical COVID-19 (published 2 September 2020);
- conditional recommendation against systemic corticosteroids in patients with non-severe COVID-19 (published 2 September 2020).
Other COVID-19 therapeutics that are currently under consideration by WHO include molnupiravir, fluvoxamine, nirmatrelvir/ritonavir, colchicine and anticoagulants. This guideline will be updated if/when sufficient new evidence warrants this.
Download Now
